Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma

We spotlight the promising preliminary findings reported by Goldsmith et al. of a phase 1 first-in-child study showcasing the safety and efficacy of lorlatinib against treatment-refractory or relapsed ALK-driven neuroblastoma.(1)

Detalles Bibliográficos
Autores principales: Suk, Yujin, Singh, Sheila K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313925/
https://www.ncbi.nlm.nih.gov/pubmed/37343514
http://dx.doi.org/10.1016/j.xcrm.2023.101071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313925/
https://www.ncbi.nlm.nih.gov/pubmed/37343514
http://dx.doi.org/10.1016/j.xcrm.2023.101071

Ejemplares similares